Nuwellis CEO Targets Pediatric Expansion to 5 kg, Leverages Rendiatech Buy to Boost ICU Diagnostics
NUWE•Nuwellis delivered 26% year-over-year revenue growth and a 70.1% gross margin in Q1 2026, a 14-percentage-point y/y improvement. Incoming CEO Mike McCormick aims to expand Aquadex pediatric use to children down to 5 kg and leverage last year’s Rendiatech acquisition to add ICU kidney function monitoring.
1. Strong Q1 Performance
Nuwellis achieved 26% year-over-year revenue growth and improved gross margin to 70.1% in Q1 2026, a 14-percentage-point increase compared to Q1 2025, reflecting disciplined execution and focused resource deployment.
2. Pediatric Expansion Strategy
Incoming CEO Mike McCormick plans to extend Aquadex use to pediatric patients weighing as little as 5 kg by leveraging existing clinical data and FDA engagement, aiming to broaden the addressable market in critical care pediatrics.
3. Rendiatech Acquisition Enhances ICU Portfolio
The acquisition of Rendiatech adds automated kidney function monitoring technology to Nuwellis' cardiorenal platform, strengthening its ICU product suite and creating cross-selling opportunities with the Aquadex fluid management system.
